logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5662.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5662.produseast1
Showing 1 - 3 of 3 Items
Showing 1 - 3 of 3 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Review

The status of combination therapy for visceral leishmaniasis: an updated review

van Griensven J, Dorlo TPC, Diro EGJ, Costa CH, Burza S
2024-01-01 • Lancet Infectious Diseases
2024-01-01 • Lancet Infectious Diseases
For the past 15 years, trials of combination therapy options for visceral leishmaniasis have been conducted with the aim of identifying effective, and safe treatment regimens that were s...
Journal Article
|
Review

New insights into leishmaniasis in the immunosuppressed

Akuffo H, Costa CH, van Griensven J, Burza S, Moreno J,  et al.
2018-05-10 • PLOS Neglected Tropical Diseases
2018-05-10 • PLOS Neglected Tropical Diseases
Immunosuppression contributes significantly to the caseload of visceral leishmaniasis (VL). HIV coinfection, solid organ transplantation, malnutrition, and helminth infections are the mo...
Journal Article
|
Research

Who Is a typical patient with visceral leishmaniasis? Characterizing the demographic and nutritional profile of patients in Brazil, East Africa, and South Asia

Harhay MO, Olliaro PL, Vaillant M, Chappuis F, Angeles Lima M,  et al.
2011-04-05 • American Journal of Tropical Medicine and Hygiene
2011-04-05 • American Journal of Tropical Medicine and Hygiene
Drug-dosing recommendations for visceral leishmaniasis (VL) treatment are based on the patients' weight or age. A current lack of demographic and anthropometric data on patients hinders ...